5F-PB-22
5F-PB-22 (5F-QUPIC or Qu inolin-8-yl 1-fluoro P entyl-1H- I ndole-3-8- C arboxylate) is a designer drug which acts as a cannabinoid agonist.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
5F-PB-22 (5F-QUPIC or Qu inolin-8-yl 1-fluoro P entyl-1H- I ndole-3-8- C arboxylate) is a designer drug which acts as a cannabinoid agonist. The structure of 5F-PB-22 appears to have been designed with an understanding of structure–activity relationships within the indole class of cannabinoids. The indazole analogue 5F-NPB-22 (5F-QUPINAC) is known.
Pharmacology
5F-PB-22 acts as a full agonist with a binding affinity of 0.468 nM at CB 1 and 0.633 nM at CB 2 cannabinoid receptors.
Legal status
As of October 2015 5F-PB-22 is a controlled substance in China. In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use. In the United Kingdom, 5F-PB-22 is now classified and controlled as a Class B drug, following the November 2016 amendment to the Misuse of Drugs Act 1971.
Several other synthetic cannabinoids structurally related to JWH-018, like 5F-PB-22, were also classified in this amendment.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1373293539 under CC BY-SA 4.0; modifications have been made.